

Date: 6<sup>th</sup> August, 2021

To,  
The Manager,  
The BSE Limited  
1st Floor, Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

Dear Sir,

**Sub: Outcome of Board Meeting**

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter ended on 30<sup>th</sup> June, 2021.

We enclose herewith the following:

- 1) Consolidated Unaudited Financial Results of the Company for the quarter ended on 30<sup>th</sup> June, 2021.
- 2) Standalone Unaudited Financial Results of the Company for the quarter ended on 30<sup>th</sup> June, 2021.
- 3) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 2:30 p.m. and the time of conclusion was 3:50 p.m.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully,  
**For Alembic Limited**

  
**Drigesh Mittal**  
**Company Secretary**



Encl.: A/a

**ALEMBIC LIMITED**

**Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2021**

Sr. No.	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	Year Ended 31.03.2021 (Audited)
1	Revenue from Operations	2,082	2,889	1,339	7,352
2	Other Income	196	177	282	1,027
3	<b>Total Income</b>	<b>2,278</b>	<b>3,066</b>	<b>1,621</b>	<b>8,379</b>
4	<b>Expenses</b>				
	Cost of Materials Consumed	234	405	253	1,177
	Cost of Construction	248	1,094	0	1,286
	Changes in Inventories of Finished Goods and WIP	304	(239)	72	(239)
	Employee Benefit Expenses	547	501	620	2,260
	Finance Costs	10	9	9	36
	Depreciation and amortisation expense	113	103	93	394
	Other Expenses	341	733	320	1,761
	<b>Total Expenses</b>	<b>1,797</b>	<b>2,607</b>	<b>1,367</b>	<b>6,675</b>
5	<b>Profit Before Tax</b>	<b>481</b>	<b>459</b>	<b>254</b>	<b>1,704</b>
6	<b>Tax Expenses</b>				
	Current Tax	88	93	12	290
	Deferred Tax	8	7	31	35
	Short / (Excess) Provision of earlier years	-	(6)	-	(6)
7	<b>Net Profit after tax for the Period</b>	<b>384</b>	<b>364</b>	<b>211</b>	<b>1,384</b>
8	<b>Share of Associate's Profit</b>	<b>4,522</b>	<b>6,830</b>	<b>8,641</b>	<b>32,900</b>
9	<b>Net Profit after tax and Share of Associate's Profit</b>	<b>4,906</b>	<b>7,194</b>	<b>8,852</b>	<b>34,284</b>
10	<b>Other Comprehensive Income</b>				
	A (i) Items that will not be reclassified to Profit or Loss	(5,548)	27,164	3,558	38,992
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	650	(3,124)	(390)	(4,452)
	B (i) Items that will be reclassified to Profit or Loss	53	4	(8)	(75)
11	<b>Total Comprehensive Income/(Loss) for the Period</b>	<b>62</b>	<b>31,238</b>	<b>12,011</b>	<b>68,749</b>
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				1,80,277
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	1.91	2.80	3.45	13.35





Alembic Limited  
Segment wise Consolidated Revenue and Results

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	<b>Segment Revenue</b>				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,069	716	727	2,849
	b. Real Estate Business	1,013	2,173	612	4,502
	<b>Total Income from Operations (Net)</b>	<b>2,082</b>	<b>2,889</b>	<b>1,339</b>	<b>7,352</b>
2	<b>Segment Results (Profit +)/ Loss (-) before Taxes and interest from each segment)</b>				
	a. Active Pharmaceutical Ingredients Business	141	(163)	(52)	(128)
	b. Real Estate Business	277	571	100	1,312
	<b>Total</b>	<b>418</b>	<b>408</b>	<b>48</b>	<b>1,184</b>
	Unallocable Income and Expenditure				
	(i) Interest Expense	(10)	(9)	(9)	(36)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	69	(89)	151	115
	(iii) Other Income / (Expense)	4	150	63	442
	<b>Total Profit Before Tax</b>	<b>481</b>	<b>459</b>	<b>254</b>	<b>1,704</b>
3	<b>Segment Assets</b>				
	a. Active Pharmaceutical Ingredients Business	15,115	15,445	15,012	15,445
	b. Real Estate Business	22,416	21,494	13,798	21,494
	c. Unallocated	2,02,840	2,03,958	1,30,787	2,03,958
	<b>Total</b>	<b>2,40,370</b>	<b>2,40,896</b>	<b>1,59,597</b>	<b>2,40,896</b>
4	<b>Segment Liabilities</b>				
	a. Active Pharmaceutical Ingredients Business	1,896	1,712	1,653	1,712
	b. Real Estate Business	4,661	4,819	3,504	4,819
	c. Unallocated	4,048	4,663	624	4,663
	<b>Total</b>	<b>10,605</b>	<b>11,193</b>	<b>5,781</b>	<b>11,193</b>

**Notes:**

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- During the quarter ended 30th June 2021, due to resurgence of Covid-19, the Real Estate segment was adversely impacted with slow-down in construction activities, new residential bookings and rental activities. The API segment, being a part of essential services is largely unaffected.  
The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited



*Chirayu Amin*  
Chirayu Amin  
Chairman

Place : London  
Date : 6th August, 2021





**Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2021**

Sr. No.	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	Year Ended 31.03.2021 (Audited)
1	Revenue from Operations	2,039	2,854	1,310	7,230
2	Other Income	196	172	281	997
3	<b>Total Income</b>	<b>2,235</b>	<b>3,026</b>	<b>1,591</b>	<b>8,227</b>
4	<b>Expenses</b>				
	Cost of Materials Consumed	234	405	253	1,177
	Cost of Construction	248	1,094	0	1,286
	Changes in Inventories of Finished Goods and WIP	304	(239)	72	(239)
	Employee Benefit Expenses	547	501	620	2,260
	Finance Costs	7	7	6	27
	Depreciation and amortisation expense	104	100	93	391
	Other Expenses	319	705	296	1,673
	<b>Total Expenses</b>	<b>1,764</b>	<b>2,573</b>	<b>1,341</b>	<b>6,575</b>
5	<b>Profit Before Tax</b>	<b>471</b>	<b>453</b>	<b>250</b>	<b>1,652</b>
6	<b>Tax Expenses</b>				
	Current Tax	88	93	12	290
	Deferred Tax	8	3	31	31
	Short / (Excess) Provision of earlier years	-	(6)	-	(6)
7	<b>Net Profit after tax for the Period</b>	<b>375</b>	<b>363</b>	<b>207</b>	<b>1,336</b>
8	<b>Other Comprehensive Income</b>				
	(i) Items that will not be reclassified to Profit or Loss	(5,392)	27,003	3,751	39,035
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	624	(3,096)	(424)	(4,458)
9	<b>Total Comprehensive Income/(Loss) for the Period</b>	<b>(4,394)</b>	<b>24,270</b>	<b>3,534</b>	<b>35,913</b>
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				33,256
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.15	0.14	0.08	0.52






Alembic Limited  
Segment wise Standalone Revenue and Results

Sr. No.	Particulars	Quarter Ended			Rs. In Lakhs
		30.06.2021	31.03.2021	30.06.2020	Year Ended
		(Unaudited)	(Audited)	(Unaudited)	31.03.2021
1	<b>Segment Revenue</b>				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,069	716	727	2,849
	b. Real Estate Business	969	2,138	582	4,381
	<b>Total Income from Operations (Net)</b>	<b>2,039</b>	<b>2,854</b>	<b>1,310</b>	<b>7,230</b>
2	<b>Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)</b>				
	a. Active Pharmaceutical Ingredients Business	141	(163)	(52)	(128)
	b. Real Estate Business	264	562	93	1,250
	<b>Total</b>	<b>406</b>	<b>399</b>	<b>42</b>	<b>1,122</b>
	Unallocable Income and Expenditure				
	(i) Interest Expense	(7)	(7)	(6)	(27)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	69	(89)	151	115
	(iii) Other Income / (Expense)	4	150	63	442
	<b>Total Profit Before Tax</b>	<b>471</b>	<b>453</b>	<b>250</b>	<b>1,652</b>
3	<b>Segment Assets</b>				
	a. Active Pharmaceutical Ingredients Business	15,115	15,445	15,012	15,445
	b. Real Estate Business	21,710	20,284	13,707	20,284
	c. Unallocated	51,836	57,917	28,775	57,917
	<b>Total</b>	<b>88,661</b>	<b>93,645</b>	<b>57,494</b>	<b>93,645</b>
4	<b>Segment Liabilities</b>				
	a. Active Pharmaceutical Ingredients Business	1,896	1,712	1,653	1,712
	b. Real Estate Business	4,434	4,594	3,372	4,594
	c. Unallocated	4,043	4,658	624	4,658
	<b>Total</b>	<b>10,373</b>	<b>10,963</b>	<b>5,649</b>	<b>10,963</b>

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- During the quarter ended 30st June 2021, due to resurgence of Covid-19, the Real Estate segment was adversely impacted with slow-down in construction activities, new residential bookings and rental activities. The API segment, being a part of essential services is largely unaffected.  
The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited



Chirayu Amin  
Chairman

Place : London  
Date : 6th August, 2021





Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> June, 2021 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

4. The statement includes results of the following entities:
  - i. Alembic City Limited (Subsidiary)
  - ii. Alembic Pharmaceuticals Limited (Associate)





5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 165.81 lakhs, total net loss after tax of Rs. 27.08 Lakhs and total comprehensive loss of Rs. 27.14 Lakhs for the quarter ended 30<sup>th</sup> June, 2021. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 4,521.99 Lakhs and total comprehensive income of Rs. 4,446.43 lakhs quarter ended 30<sup>th</sup> June, 2021, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 06<sup>th</sup> August, 2021

UDIN : 21042005AAAAMB9451





Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30<sup>th</sup> June, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the





Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 06<sup>th</sup> August, 2021

UDIN : 21042005AAAAMA3254

